Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a sleep aid curb opioid and stimulant use?

NCT ID NCT05546515

Symptom relief Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether suvorexant, a sleep medication, can reduce drug use and cravings while improving sleep and stress in people being treated for both opioid and stimulant use disorders. Twenty adults stable on methadone or buprenorphine took either suvorexant or a placebo for up to 30 days. Researchers measured drug use through urine tests and tracked sleep quality.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Suvorexant (a sleep medication)
What this could lead to
If it works, this could point toward a new way to help people in treatment for opioid use disorder also reduce stimulant use and improve sleep.
What could go wrong
This was a very small, early-phase study with only 20 participants, so results may not apply to everyone. The drug may not show clear benefits over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

20 people

The number who actually took part.

Started

Dec 2022

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Ages 18-65, 2. Meet criteria for stimulant use disorder, based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) 3. Currently receiving methadone or buprenorphine treatment for OUD and considered to be stable on current dose for at least 30 days 4. Willingness to engage with study protocol 5. Use of birth control (as appropriate) Exclusion criteria: 1. Psychiatric or medical conditions that are judged by the investigators to interfere with participation or that are contraindicated for use with SUVO 2. Pregnant or breastfeeding 3. Current use of benzodiazepines, tranquilizers, or other schedule IV sleep medications 4. Moderate or severe substance use disorder other than opioid or stimulant use disorder 5. SUVO consumption in the last 30 days 6. Use of medications that are contraindicated with the study 7. Past 30-day suicidal behavior 8. Use of continuous positive airway pressure (CPAP) device for sleep apnea

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Opioid use disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Chemically-Induced Disorders Narcotic-Related Disorders opiate dependence substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Opioid use disorder Stimulant use disorder

Contacts and locations

Locations

  • Behavioral Pharmacology Research Unit at the Johns Hopkins Bayview Medical Center

    Baltimore, Maryland, 21224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.